The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Oskar Hansson(Eli Lilly (United States)), Charlotte E. Teunissen(Amsterdam Neuroscience), Rebecca M. Edelmayer(Alzheimer's Association), Adam L. Boxer(University of California, San Francisco), María C. Carrillo(Brigham and Women's Hospital), Gil D. Rabinovici(University of California, San Francisco), Henrik Zetterberg(University of Wisconsin–Madison), Reisa A. Sperling(Harvard University), Michelle M. Mielke(Wake Forest University), Stephen Salloway(Providence College)
Cited by 589
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
|Alzheimer s & Dementia|2012|3.2k